NL-OMON52680招募中3 期
Glioblastoma, Optimizing Logistics and Dose (GOLD). - GOLD study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 474 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 474
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histological diagnosis of GBM with any MGMT-promotor methylation status and
- •IDH1 mutation
- •status by multidisciplinary neuro-oncology tumor board.
- •Age >= 18 years.
- •KPS >=70.
- •Surgical biopsy or resection performed.
- •Decision of chemoradiation following the Stupp-protocol by multidisciplinary
- •neuro-oncology
- •tumour board.
排除标准
- •Participation in a competing trial.
- •Prior overlapping intracranial radiotherapy.
- •Known carcinoma < 3 years ago (excluding Carcinoma in situ of the cervix,
- •carcinoma, squamous cell carcinoma of the skin) requiring immediate
- •treatment interfering with
- •study therapy and with worse prognosis than glioblastoma.
- •Maximum diameter > 6cm (~ reflecting a spherical tumor volume of 125 cc).
- •Unwilling or unable to undergo MRI scans.
- •Contra-indication for gadolinium contrast.
- •Women with childbearing potential without adequate contraception.
研究者
相似试验
招募中
不适用
Glioblastoma targeted treatment option maximization by WGS (GLOW);Maximizing treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnosticsGlioblstomamalignant brain tumor grade IV1002921110009720NL-OMON54315Haaglanden Medisch Centrum235
已完成
不适用
Radiotherapy for glioblastoma: Dose escalation trial of IMRT after hyperbaric oxygen therapyGlioblastomaJPRN-UMIN000027623Tobata Kyoritsu Hospital18
进行中（未招募）
不适用
First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-VaxPatients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide.MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015979-27-ATActivartis Biotech GmbH76
进行中（未招募）
1 期
Safety and Tolerability of Fb-PMT in Recurrent GlioblastomaGlioma, MalignantNCT05226494NanoPharmaceuticals LLC34
招募中
早期 1 期
Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent GlioblastomaRecurring GlioblastomaNCT05914935Binhai Hospital of Fujian Medical University6